[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1971

Production of Macrophage Inhibitory Factor by Patients With Leprosy

Author Affiliations

Miami, Fla

From the Department of Dermatology, University of Miami Medical School, and Dermatology Service, Veterans' Administration Hospital, Miami, Fla. Dr. Katz is now with the Dermatology Service, Walter Reed General Hospital, Washington, DC.

Arch Dermatol. 1971;103(4):358-361. doi:10.1001/archderm.1971.04000160008002
Abstract

Patients with lepromatous (low resistance) leprosy exhibit depressed cell-mediated immunologic reactivity. This is reflected by anergic responses to intradermal injection of various antigens, including lepromin, by relative inability to become sensitive to haptenes (dinitrochlorobenzene), and by poor blastogenic response of lymphocytes to various mitogens in cell culture. Patients with tuberculoid (high resistance) leprosy usually respond normally to these stimuli. Ability of lymphocytes to produce macrophage migration inhibition factor (MIF) has been shown to correlate with patient's ability to exhibit cell-mediated delayed-type hypersensitivity reactions. Lymphocytes of patients with lepromatous leprosy who are anergic fail to produce or produce only small amounts of MIF in response to lepromin in vitro, but lymphocytes of patients with tuberculoid leprosy who exhibit normal cell-mediated reactions respond to lepromin in vitro by production of greater amounts of MIF.

×